Neoadjuvant therapy for oligometastatic colorectal cancer

Czech version

Authors: J. Tomášek ¹ ; T. Staněk ²
Authors‘ workplace: Klinika komplexní, onkologické péče, LF MU a MOÚ, Brno ¹; Klinika operační onkologie, LF MU a MOÚ, Brno ²
Published in: Rozhl. Chir., 2025, roč. 104, č. 3, s. 101-104.
Category: Review
doi: https://doi.org/10.48095/ccrvch2025101

Overview

Every patient with oligometastatic disease should be discussed within a multidisciplinary team.The intention of treating oligometastatic disease is curative in most cases. Surgical treatment is essential, and can be combined with ablation methods. Oncological criteria that describe the risk of progression/relapse help select patients who benefit most from neoadjuvant/perioperative chemotherapy. For optimal selection of systemic treatment for metastatic colorectal cancer, knowledge of predictive molecular factors is necessary. These include determination of RAS, BRAF and MMR/MSI. The basis of systemic treatment is chemotherapy based on combinations of fluoropyrimidines, oxaliplatin or irinotecan. A special group includes patients with dMMR/MSI-high tumors, which are very sensitive to the treatment with modern immunotherapy with checkpoint inhibitors. The question of the indication of immunotherapy in the case of resectable metastases has not been resolved yet.

Keywords:

colorectal cancer – oligometastatic – resectable metastases – neoadjuvant/perioperative chemotherapy

Sources

1. Cervantes A, Adam R, Roselló S et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34(1): 10–32. doi: 10.1016/j.annonc.2022.10.003.

2. Bischof DA, Clary BM, Maithel SK et al. Surgical management of disappearing colorectal liver metastases. Br J Surg 2013; 100(11): 1414–1420. doi: 10.1002/bjs.9213.

3. Ciliberto D, Prati U, Roveda L et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep 2012; 27(6): 1849–1856. doi: 10.3892/or.2012.1740.

4. Wang ZM, Chen YY, Chen FF et al. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol 2015; 41(9): 1197–1203. doi: 10.1016/j.ejso.2015.05.020.

5. Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol 2015; 22(9): 3070–3078. doi: 10.1245/s10434-014-4354-6.

6. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14(12): 1208–1215. doi: 10.1016/S1470-2045(13)70447-9.

7. Bridgewater JA, Pugh SA, Maishman T et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21(3): 398–411. doi: 10.1016/S1470-2045(19)30798-3.

8. NCCN guidelines. Colon cancer, version 4.2024. 2024 [online]. Dostupné z: www.nccn.org.

MUDr. Jiří Tomášek, Ph.D.

Klinika komplexní onkologické péče

LF MU a MOÚ

Žlutý kopec 7

656 53 Brno

jiri.tomasek@mou.cz